Sat Nov 1 10:55:32 SGT 2014  
SINGAPORE
VACCINE™
    Vaccine, Singapore (SG)

Vaccine, Singapore (SG)

Summary

Vaccine, Singapore (SG) @singaporevaccine_com: vaccine jab/shot/injection schedule, to vaccinate against the infection, to immunise against infectious disease, Singapore. Private and confidential service. Definitions, references, and latest news.

Description

Vaccine types available for vaccination / immunisation (uk) / immunization (us) :

Vaccine Against Disease Age D
o
s
e
s
Dose schedule Price
per
dose
(SG$)
Live attenuated
MMR vaccine ≥12m 1 $70/=
Measles virus Measles
Mumps virus Mumps
Rubella virus Rubella
Varilrix™ Varicella zoster virus
HHV-3
Varicella Chickenpox 12m-12y 1 $121/=
≥13y 2 6-10w interval
Zostavax™ Herpes zoster Shingles ≥50y 1 $400/=
Stamaril® Yellow fever virus Yellow fever 9m-59y 1 10 yearly $250/=
Inactivated / Whole / Viral & Bacterial
Rabipur® Rabies virus Rabies any 3 d 0, 7, & 21 or 28 $call/=
Ixiaro® Japanese encephalitis virus Japanese encephalitis ≥17y 2 2nd: 28d after 1st $386/=
1 Booster: 12-24m after 2nd
Dukoral® Vibrio cholerae Cholera 2-6y 3 1-6w interval $113/=
1 Booster: 6m after 3rd
≥6y 2 1-6w interval
1 Booster: 2y after 2nd
Inactivated / Fractional / Protein
Intanza™ Influenza virus Influenza 18-59y 1 1 yearly $30/=
Fluarix™ Influenza virus Influenza 6-36m ½ 1 yearly $30/=
>3y 1
Tetavax Clostridium tetani Tetanus adults 3 1-2m interval
3rd @ 6-12m
after 2nd
$30/=
booster 1 10 yearly
Boostrix® ≥4y 1 <10 yearly $70/=
Corynebacterium diphtheriae Diphtheria
Clostridium tetani Tetanus
Bordetella pertussis Pertussis
Whooping cough
Inactivated / Fractional / Polysaccharide / Pure
Typhim Vi® Salmonella typhi Typhoid fever >5y 1 3 yearly $48/=
Mencevax® ACWY Neisseria meningitidis
types A, C, W-135
and Y
Meningococcal meningitis >2y 1 $80/=
Inactivated / Fractional / Polysaccharide / Conjugate
Menactra® Neisseria meningitidis
types A, C, W-135
and Y
Meningococcal meningitis 2-55y 1 $220/=
Prevenar 13® (SG) /
Prevnar 13® (US)
Streptococcus pneumoniae
types 1, 3, 4, 5,
6A, 6B, 7F, 9V, 14,
18C, 19A, 19F, 23F
Pneumococcal infection 6w-6m 4 1m interval
4th @ 12-15m
$274/=
7-11m 2 1m interval
12-23m 2 2m interval
2-5y 1
≥50y 1

If the clinic attendance is just for vaccination alone, no additional consultation fees are charged.

Testing for immunity against the following is available:

Virus Antibody Test Price
Varicella zoster virus Varicella Zoster IgG Antibody $44/=
Measles virus Measles IgG Antibody $90/=
Rubella virus Rubella IgG Antibody $24/=
Hepatitis A virus Hepatitis A IgG Antibody $30/=
Hepatitis B virus Hepatitis B surface Antibody $10/=

Other vaccines not stocked

References

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Vaccine, Singapore (SG)
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

References


Latest News

Interim estimates of the effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2014.
Fri, 31 Oct 2014 16:20:03 +0100 | Euro Surveill
Authors: Turner N, Pierse N, Huang Q, Radke S, Bissielo A, Thompson M, Kelly H, on behalf of the SHIVERS investigation team

Decreased varicella and increased herpes zoster incidence at a sentinel medical deputising service in a setting of increasing varicella vaccine coverage in Victoria, Australia, 1998 to 2012.
Fri, 31 Oct 2014 16:20:03 +0100 | Euro Surveill
Authors: Kelly H, Grant K, Gidding H, Carville K

Profectus BioSciences gets another $9.5 million for Ebola vaccine work
Fri, 31 Oct 2014 15:52:00 +0100 | bizjournals.com Health Care:Physician Practices headlines
Baltimore pharmaceutical firm Profectus BioSciences Inc. has received a $9.5 million grant from the Department of Defense for a phase 1 clinical trial of its Ebola vaccine.

Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines
Fri, 31 Oct 2014 01:24:02 +0100 | AIDS
Conclusion:These results inform designs of initial human studies combining separately optimized T-cell and B-cell HIV-1 vaccines into a single regimen. (Source: AIDS)

Haemophilus Species Bacteremia in Adults in the 21st Century: Review of 45 Episodes Over an 11-Year Period in a Large Community Teaching Hospital
Fri, 31 Oct 2014 01:23:50 +0100 | Infectious Diseases in Clinical Practice
ConclusionsHaemophilus species bacteremia is not uncommon in the adult population, is most commonly caused by H. influenzae (86.6%), is most prevalent in the eighth and ninth decades of life, and has a significant mortality rate (13.3%) despite the uniformly appropriate initial empiric antimicrobial therapy. Pneumonia is the most common presenting manifestation causing 68.9% of all cases of HB in our series. (Source: Infectious Diseases in Clinical Practice)

[In Depth] The Ebola vaccine underdog
Fri, 31 Oct 2014 00:00:00 +0100 | Science: Current Issue
NewLink Genetics says it might have enough doses ready by spring to vaccinate most people at risk.

Association between process quality measures for heart failure and mortality among US veterans
Fri, 31 Oct 2014 00:00:00 +0100 | American Heart Journal
Conclusions Receipt of care processes related to recommended medications and vaccinations were associated with lower 30-day and/or 1-year risk-adjusted mortality in patients with HF. Receipt of care processes that assess patient counseling or chart documentation was not related to lower mortality. (Source: American Heart Journal)

Will Ebola kill you? It depends on your genes
Thu, 30 Oct 2014 22:59:39 +0100 | the Mail online | Health
Scientists at Washington University believe their study has identified genetic factors behind the mild-to-deadly range of reactions to the virus in a group of mice, paving the way for further studies and hopes to develop drugs and vaccines. (Source: the Mail online | Health)

Paul Stoffels on Ebola
Thu, 30 Oct 2014 19:25:32 +0100 | PHRMA
Stepping Up Our Response to Ebola

John P Howe on Ebola
Thu, 30 Oct 2014 19:03:24 +0100 | PHRMA
The Ebola Outbreak: How Public-Private Partnerships Search for Solutions in Sierra Leone